← BASF overview
BASF SEBAS.XETRA

Why is BASF (BAS.XETRA) moving?

Q3 2026
▲3▼1

BASF's coatings sale, buyback, and growth bets drive Q3

  • Coatings sale and buyback BASF completed the €7.7bn sale of its coatings business to Carlyle, boosting profit and funding a €1bn share buyback. This returns cash to shareholders and sharpens focus on core chemicals.

    Major portfolio move that directly lifted profit and shareholder returns.

  • Strong earnings and pricing power Q2 net income surged to €4.14bn, and price hikes for MDI and TDI (key chemicals) lifted margins. This shows BASF can pass on costs and benefit from tight supply.

    Earnings surge and pricing power are core drivers of investor sentiment.

  • Growth investments and potential Evonik deal New products, partnerships, capacity expansion, and AI/medical-plastics investment support future growth. A possible renewed Evonik bid could add ~20% to EPS and cash flow, though integration risks remain.

    Growth initiatives and M&A potential are forward-looking positives.

  • Regulatory and supply risks The EU emissions overhaul could raise costs, and record-low Rhine water threatens production and supply, as BASF sources ~40% of raw materials via the river. These are real headwinds.

    Environmental and logistical risks could pressure operations and costs.

September 2026
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

Latest
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

August 2026
▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

July 2026
▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.